Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Equity Average (2016 - 2025)

Historic Equity Average for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to -$281.1 million.

  • Karyopharm Therapeutics' Equity Average fell 6263.89% to -$281.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$281.1 million, marking a year-over-year decrease of 6263.89%. This contributed to the annual value of -$239.5 million for FY2025, which is 4863.71% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Equity Average stood at -$281.1 million, which was down 6263.89% from -$254.1 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Equity Average peaked at $5.5 million during Q1 2021, and registered a low of -$281.1 million during Q4 2025.
  • Its 5-year average for Equity Average is -$126.0 million, with a median of -$111.4 million in 2021.
  • In the last 5 years, Karyopharm Therapeutics' Equity Average tumbled by 159231.62% in 2022 and then surged by 6200.97% in 2023.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Equity Average stood at -$102.8 million in 2021, then grew by 23.69% to -$78.5 million in 2022, then tumbled by 50.76% to -$118.3 million in 2023, then tumbled by 46.1% to -$172.8 million in 2024, then plummeted by 62.64% to -$281.1 million in 2025.
  • Its last three reported values are -$281.1 million in Q4 2025, -$254.1 million for Q3 2025, and -$222.4 million during Q2 2025.